glp-1 regain weight based drugs: Could Elon Musk's loss weapon help us, too? GLP-1 analysis suggests people regained

Contact your GP or diabetes care team if you experience: Severe or worsening cognitive symptoms that interfere with daily activities, work, or safety Symptoms of hypoglycaemia including confusion, shakiness, sweating, rapid heartbeat, or difficulty speakingparticularly if recurrent Persistent brain fog lasting beyond the first few weeks of treatment or following a dose increase New neurological symptoms such as severe headaches, visual changes, weakness, numbness, or difficulty with speech or coordination Signs of dehydration including dark urine, dizziness, dry mouth, or reduced urination Mood changes including depression, anxiety, or unusual thoughts Inability to keep fluids down for 24 hours or severe, persistent vomiting Seek urgent medical attention (call 999 or attend A&E) if you experience severe confusion, loss of consciousness, seizures, or any symptoms suggesting a stroke or other acute neurological event

By 2026, it is widely regarded as the benchmark GLP-1 compound against which newer weight loss therapies are measured

The Danish firm is working toward its own oral version of Ozempic and is seeking approvals for pediatric use, which would significantly boost its addressable market

Consoli A, Formoso G, Baldassarre MPA, et al

Life-saving LVAD implants In October 2020, Mike received a Left Ventricular Assist Device (LVAD) implant to support his heart